Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Roche Shares Tick Higher After FDA Approves Influenza Drug in Children 5 and Over

Published 08/12/2022, 08:12 AM
Updated 08/12/2022, 08:14 AM
© Reuters.

By Scott Kanowsky 

Investing.com -- Roche Holding AG (SIX:RO) stock rose on Friday after the Swiss drugmaker announced it has received approval from the U.S. Food and Drug Administration for its drug to treat influenza in children.

The treatment, marketed under the name Xofluza, is designed for otherwise healthy children aged five to less than 12 years of age who have had symptoms of acute uncomplicated influenza for less than two days. It is the first single-dose oral influenza medicine given the green light by U.S. authorities in this age group.

The FDA also signed off on the use of Xofluza for the prevention of influenza in children in this age range who have come into contact with someone with the disease.

Xofluza is already approved by the FDA for people 12 years of age and older.

As of 08:09 EST (12:09 GMT), shares in Roche were trading higher by 0.31%, pulling back slightly from earlier gains.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.